Primary mesenchymal stem cells as a vaccine platform
AssigneeThe Administrators of the Tulane Educational Fund
InventorsSuzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
Life of this patent
Estimating the term…
Abstract
Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
Claims17
Episomally transfected primary mesenchymal stems cells (ETP-MSC) which episomally express at least one polypeptide consisting of an antigenic polypeptide relating to a pathogen;
- wherein the antigenic polypeptide has the amino acid sequence of a natural polypeptide from the pathogen or has an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions.
Dependencies are inferred from the claim text.